COVID-19 & CancerFree Coronavirus vs. oncology: Meeting cancellations, travel restrictions, fears about drug supply chain March 04, 2020Vol.46 No.10By Alexandria Carolan
FDA approved 11 new agents, 30 supplemental indications in cancer in 2019 February 28, 2020Vol.46 No.09By Alexandria Carolan
ODAC: Thumbs up for Eli Lilly’s Cyramza, thumbs down for STEBA’s Tookad February 28, 2020Vol.46 No.09By Paul Goldberg
Trials & Tribulations Lung cancer: Significant progress leads to record annual decrease in cancer mortality February 21, 2020Vol.46 No.08By Fred R. Hirsch
Coalition of cancer groups urges Congress to include clinical trial-related coverage under Medicaid February 21, 2020Vol.46 No.08By Alexandria Carolan
25 years ago: Here is The Cancer Letter’s coverage of Michael Milken’s 1995 cancer summit February 21, 2020Vol.46 No.08By Paul Goldberg
Trump grants clemency to Michael Milken, financier whose ideas brought new money & swagger into cancer politics, research February 21, 2020Vol.46 No.08By Paul Goldberg
FreeGuest Editorial Lung-MAP: A five-year recap on the first master protocol trial in cancer research February 21, 2020Vol.46 No.08By Roy S. Herbst, Lyudmila Bazhenova, Joel Neal and Saiama N. Waqar
Ohio State expands assistance program to give out previously dispensed cancer drugs February 14, 2020Vol.46 No.07By Alexandria Carolan
